A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder

Journal of Occupational and Environmental Medicine

Volumn 50, Issue 4, 2008, Pages 428-436

  Nierenberg, Andrew A ^a   Ostacher, Michael J ^a   Huffman, Jeffrey C ^a   Ametrano, Rebecca M ^a   Fava, Maurizio ^a   Perlis, Roy H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOPAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PETHIDINE; PLACEBO; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE;

ALTERNATIVE MEDICINE; ANOREXIA; ANORGASMIA; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; APPETITE; AROUSAL; ASTHENIA; BLURRED VISION; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DAYTIME SOMNOLENCE; DELIRIUM; DIARRHEA; DISSOCIATIVE DISORDER; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FLU LIKE SYNDROME; FOOT EDEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; IMBALANCE; IMPOTENCE; INSOMNIA; IRRITABILITY; LIBIDO; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MALAISE; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; ORTHOSTATIC HYPOTENSION; PRIAPISM; PSYCHOSIS; PSYCHOTHERAPY; REMISSION; RESTLESSNESS; SEDATION; SEIZURE; SENSORY DYSFUNCTION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SHORT SURVEY; SIDE EFFECT; SOMNOLENCE; SWEATING; THERAPY EFFECT; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

EID: 42049099485     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e31816b5034     Document Type: Review

References (55)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
2. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627.
3. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet. 1997;349:1436-1442.
4. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:629-640.
5. Wittkampf KA, Naeije L, Schene AH, Huyser J, van Weert HC. Diagnostic accuracy of the mood module of the patient health questionnaire: a systematic review. Gen Hosp Psychiatry. 2007;29:388-395.
6. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006;59:493-501.
7. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
8. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62:S5-S9.
9. Perry PJ, Zeilman C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol. 1994;14:230-240.
10. Fava MRS, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry. 1995;56:52-55.
11. Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clin Ther. 1998;20:505-516.
12. Kelsey J. Dose-response relationship with venlafaxine. J Clin Psychopharmacol. 1996;16(3 Suppl 2):21S-26S.
13. Quitkin FM, Rabkin JG, Ross D, McGrath PJ. Duration of antidepressant drug-treatment - what is an adequate trial. Arch Gen Psychiatry. 1984;41:238-245.
14. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change - when should clinicians switch antidepressants? Arch Gen Psychiatry. 1996;53:785-792.
15. Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995;152:1500-1503.
16. Lavori PW, Keller MB, Mueller TI, Scheftner W, Favrod J, Coryell W. Recurrence after recovery in unipolar MDD - an observational follow-up-study of clinical predictors and somatic treatment as a mediating factor. Int J Methods Psychiatr Res. 1994;4:211-229.
17. Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry. 2003;64:13-17.
18. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:653-661.
19. Joyce P, Paykel E. Predictors of drug response in depression. Arch Gen Psychiatry. 1989;46:89-99.
20. Stewart J, McGrath PJ, Rabkin JG, Quitkin FM. Atypical depression. A valid clinical entity? Psychiatr Clin North Am. 1993;16:479-495.
21. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF. Major depressive subtypes and treatment response. Biol Psychiatry. 1997;42:568-576.
22. Nierenberg AA, Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M. Course and treatment of atypical depression. J Clin Psychiatry. 1998;59:5-9.
23. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50:345-350.
24. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord. 2000;59:119-126.
25. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61:863-867.
26. Raeder MB, Bjelland I, Emil Vollset S, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland health study. J Clin Psychiatry. 2006;67:1974-1982.
27. Lader M. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs. 2007;67:1657-1663.
28. Warner CH, Bobo W, Warner C, Reid S, Rachel J. Antidepressant discontinuation syndrome. Am Fam Physician. 2006;74:449-456.
29. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry. 2006;67:27-30
30. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3:13-37.
31. Lieberman JA, Greenhouse J, Hamer RM, et al. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology. 2005;30:445-460.
32. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997;154:1760-1762.
33. Detke MJ, Lu Y Goldstein DJ, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36:383-390.
34. Goldstein D, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002;63:225-231.
35. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res. 2005;39:43-53.
36. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos. 2003;31:1142-1150.
37. Hudson J, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol. 2005;20:327-341.
38. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother. 2006;6:1249-1265.
39. Roose SP, Glassman AH. Cardiovascular effects of tricyclic antidepressants in depressed patients. J Clin Psychiatry Monogr. 1989;7:1-13.
40. Anonymous, priapism with trazodone (Desyrel). Med Lett Drugs Ther. 1984;26:35.
41. Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151:1069-1072.
42. Szegedi A, Schwertfeger N. Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin Pharmacother. 2005;6:631-641.
43. Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007;68(Suppl 8):35-41.
44. Amsterdam J. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64:208-214.
45. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119-142.
46. Papakostas GI, Petersen TJ, Kinrys G et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatmentresistant major depressive disorder. J Clin Psychiatry. 2005;66:1326-1330.
47. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65:217-221.
48. Paykel E, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry. 1999;56:829-835.
49. Scott J, Teasdale JD, Paykel ES, et al. Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. Br J Psychiatry. 2000;177:440-446.
50. Fava G, Rafanelli C, Cazzaro M, Conti S, Grandi S. Well-being therapy. A novel psychotherapeutic approach for residual symptoms of affective disorders. Psychol Med. 1998;28:475-480.
51. Fava G, Rafanelli C, Grandi S, Canestrari R, Morphy MA. Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry. 1998;155:1443-1445.
52. Judd L, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97-108.
53. Judd L, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55:694-700.
54. Teasdale J, Segal Z, Williams J. How does cognitive therapy prevent depressive relapse and why should attentional control (mindfulness) training help? Behav Res Ther. 1995;33:25-29.
55. Teasdale J, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol. 2000;68:615-623.